Track Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Track Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $33.88M | Dec 23, 2020 |
| FY2020 | Sep 30, 2019 | $34.02M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $30.57M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $29.73M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $27.19M | Dec 19, 2017 |
| FY2016 | Sep 30, 2015 | $20.79M | Dec 20, 2016 |
| FY2015 | Sep 30, 2014 | $12.26M | Dec 11, 2015 |
| FY2014 | Sep 30, 2013 | $15.64M | Dec 18, 2014 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2016 | $27.19M | Dec 20, 2016 |
| FY2016 | Sep 30, 2015 | $20.79M | Dec 20, 2016 |
| FY2015 | Sep 30, 2014 | $12.26M | Dec 11, 2015 |
| FY2014 | Sep 30, 2013 | $15.64M | Dec 18, 2014 |
| FY2013 | Sep 30, 2012 | $13.11M | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | $17.96M | Jan 14, 2013 |
| FY2011 | Sep 30, 2010 | $12.45M | Dec 29, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $17.50M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $17.21M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $15.30M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $17.35M | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $21.11M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $18.65M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $19.02M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $17.20M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $15.60M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $14.78M | Dec 19, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.88M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($3.08M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($3.39M) | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | ($7.39M) | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $3.44M | Dec 16, 2022 |
| FY2021 | Sep 3, 2021 | $3.44M | Dec 16, 2021 |
| FY2021 | Sep 30, 2020 | ($118.6K) | Dec 16, 2021 |
| FY2015 | Sep 30, 2015 | ($5.67M) | Dec 11, 2015 |
| FY2015 | Sep 30, 2014 | ($8.75M) | Dec 11, 2015 |
| FY2014 | Sep 30, 2013 | ($17.92M) | Dec 18, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.24M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($1.88M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($1.54M) | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | ($2.10M) | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $4.71M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $2.76M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $1.17M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($1.65M) | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | ($4.87M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($5.66M) | Dec 19, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.80M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $2.75M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $2.74M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $2.43M | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $1.55M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $1.18M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $1.31M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $862.1K | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $1.78M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $2.42M | Dec 19, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Sep 30, 2014 | $12.89M | Dec 18, 2014 |
| FY2014 | Sep 30, 2013 | $7.68M | Dec 18, 2014 |
| FY2013 | Sep 30, 2012 | $12.62M | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | $15.65M | Jan 14, 2013 |
| FY2011 | Sep 30, 2010 | $12.13M | Dec 29, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.32M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $4.91M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $3.88M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $803.0K | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $4.82M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $4.73M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $5.07M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $6.03M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $4.15M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $907.6K | Dec 19, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $40.30M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $37.67M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $40.24M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $44.68M | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $53.52M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $47.73M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $49.38M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $48.36M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $49.15M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $52.32M | Dec 19, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $51.85M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $49.28M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $48.74M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $49.74M | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $51.15M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $48.66M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $50.28M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $46.72M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $43.17M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $43.63M | Dec 19, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($11.54M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($11.61M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2023 | ($8.49M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2022 | ($5.05M) | Dec 23, 2024 |
| FY2023 | Sep 30, 2021 | $2.37M | Dec 20, 2023 |
| FY2022 | Sep 30, 2020 | ($920.6K) | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | ($902.2K) | Dec 16, 2021 |
| FY2020 | Sep 30, 2018 | $1.64M | Dec 23, 2020 |
| FY2019 | Sep 30, 2017 | $5.98M | Jan 10, 2020 |
| FY2018 | Sep 30, 2016 | $8.69M | Dec 19, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.30M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $7.94M | Dec 19, 2025 |
| FY2025 | Sep 30, 2023 | $7.85M | Dec 19, 2025 |
| FY2024 | Sep 30, 2022 | $8.06M | Dec 23, 2024 |
| FY2023 | Sep 30, 2021 | $8.06M | Dec 20, 2023 |
| FY2023 | Sep 30, 2020 | $8.52M | Dec 20, 2023 |
| FY2021 | Sep 30, 2019 | $8.19M | Dec 16, 2021 |
| FY2020 | Sep 30, 2018 | $8.08M | Dec 23, 2020 |
| FY2019 | Sep 30, 2017 | $8.23M | Jan 10, 2020 |
| FY2018 | Sep 30, 2016 | $7.96M | Dec 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($315.15M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($312.69M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($309.61M) | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | ($306.22M) | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | ($298.83M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($302.27M) | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | ($302.15M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($299.50M) | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | ($294.07M) | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | ($289.34M) | Dec 19, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $6.76M | Dec 23, 2020 |
| FY2020 | Sep 30, 2019 | $6.90M | Dec 23, 2020 |
| FY2020 | Sep 30, 2018 | $5.45M | Dec 23, 2020 |
| FY2019 | Sep 30, 2017 | $2.03M | Jan 10, 2020 |
| FY2018 | Sep 30, 2016 | $1.77M | Dec 19, 2018 |
| FY2017 | Sep 30, 2015 | $4.90M | Dec 19, 2017 |
| FY2016 | Sep 30, 2014 | $11.10M | Dec 20, 2016 |
| FY2015 | Sep 30, 2013 | $3.38M | Dec 11, 2015 |
| FY2014 | Sep 30, 2012 | $458.0K | Dec 18, 2014 |
| FY2012 | Sep 30, 2011 | $949.7K | Jan 14, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $42.72M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $42.64M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $43.11M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $43.44M | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | $43.98M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $31.33M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | $33.83M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $33.87M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | $33.75M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | $33.59M | Dec 19, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 20, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 16, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 11.86M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | 11.86M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | 11.86M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | 11.86M | Dec 20, 2023 |
| FY2023 | Sep 30, 2021 | 11.86M | Dec 20, 2023 |
| FY2021 | Sep 30, 2020 | 11.41M | Dec 16, 2021 |
| FY2020 | Sep 30, 2019 | 11.40M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | 11.40M | Jan 10, 2020 |
| FY2018 | Sep 30, 2017 | 10.48M | Dec 19, 2018 |
| FY2017 | Sep 30, 2016 | 10.33M | Dec 19, 2017 |